Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma

Author:

Tovoli Francesco1,Negrini Giulia1,Bolondi Luigi1

Affiliation:

1. Department of Medical & Surgical Sciences, Alma Mater Studiorum-University of Bologna, Via Massarenti 9, 40138 Bologna, Italy

Abstract

Hepatocellular carcinoma is one of the most common malignancies and represents a unique challenge for physicians and patients. Treatment patterns are not uniform between areas despite efforts to promote a common protocol. Even if most hepatologists worldwide adopt the Barcelona Clinic Liver Cancer staging system, Asian and North American physicians are also independently making an effort to expand the indications of each treatment, combining therapies for better outcomes. Also, new therapeutic techniques have emerged and an increasing number of studies are trying to include these paradigm shifts into newer treatment guidelines. Controversial and diverging points in the current international guidelines are emphasized and discussed. Unanswered questions are also analyzed to identify the most needed and promising future perspectives.

Publisher

Future Medicine Ltd

Subject

Oncology,Hepatology

Reference103 articles.

1. Global cancer statistics

2. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

3. Epidemiology of primary liver cancer

4. Ferlay J, Soerjomataram I, Ervik M Globocan 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3